BamSEC and AlphaSense Join Forces
Learn More

Oruka Therapeutics Inc.

NASDAQ: ORKA    
Share price (12/20/24): $20.31    
Market cap (12/20/24): $711 million
Search in Documents
Key Exhibits
External Links

Articles of Incorporation Filter

EX-3.1
from 8-K 13 pages Oruka Therapeutics, Inc. Certificate of Designation of Preferences, Rights and Limitations of Series a Non-Voting Convertible Preferred Stock Pursuant to Section 151 of the General Corporation Law of the State of Delaware
12/34/56
EX-3.9
from 8-K 10 pages Arca Biopharma, Inc. Certificate of Designation of Preferences, Rights and Limitations of Series B Non-Voting Convertible Preferred Stock Pursuant to Section 151 of the General Corporation Law of the State of Delaware
12/34/56
EX-3.8
from 8-K 2 pages Certificate of Elimination of Series a Convertible Preferred Stock of Arca Biopharma, Inc. (Pursuant to Section 151(g) of the General Corporation Law of the State of Delaware)
12/34/56
EX-3.6
from 8-K 20 pages Amended and Restated Bylaws of Oruka Therapeutics, Inc
12/34/56
EX-3.5
from 8-K 4 pages Second Amended and Restated Certificate of Incorporation of Oruka Therapeutics, Inc
12/34/56
EX-3.4
from 8-K 2 pages Certificate of Amendment to the Amended and Restated Certificate of Incorporation of Arca Biopharma, Inc
12/34/56
EX-3.3
from 8-K 2 pages Certificate of Amendment to the Amended and Restated Certificate of Incorporation of Arca Biopharma, Inc
12/34/56
EX-3.2
from 8-K 2 pages Certificate of Amendment to the Amended and Restated Certificate of Incorporation of Arca Biopharma, Inc
12/34/56
EX-3.1
from 8-K 2 pages Certificate of Amendment to the Amended and Restated Certificate of Incorporation of Arca Biopharma, Inc
12/34/56
EX-3.6
from S-4 14 pages Oruka Therapeutics, Inc. Bylaws Adopted February 6, 2024
12/34/56
EX-3.5
from S-4 23 pages Amended and Restated Certificate of Incorporation of Oruka Therapeutics, Inc
12/34/56
EX-3.1
from 8-K 11 pages ARCA Biopharma, Inc. Certificate of Designation of Preferences, Rights and Limitations of Series B Non-Voting Convertible Preferred Stock Pursuant to Section 151 of the General Corporation Law of the State of Delaware
12/34/56
EX-3.1
from 8-K 10 pages Amended and Restated By-Laws of ARCA Biopharma, Inc. Adopted June 28, 2021
12/34/56
EX-3.1
from 8-K 1 page Certificate of Amendment of Amended and Restated Certificate of Incorporation of ARCA Biopharma, Inc
12/34/56
EX-3.1
from 8-K 2 pages Certificate of Amendment of Amended and Restated Certificate of Incorporation of ARCA Biopharma, Inc
12/34/56
EX-3.1.B
from S-1/A 13 pages ARCA Biopharma, Inc. Certificate of Designation of Preferences, Rights and Limitations of Series a Convertible Preferred Stock Pursuant to Section 151 of the Delaware General Corporation Law Terms of Preferred Stock
12/34/56
EX-3
from SC 13D 29 pages Subscription Agreement
12/34/56
EX-3.2
from 10-Q 10 pages Second Amended and Restated By-Laws of ARCA Biopharma, Inc. Adopted November 13, 2009
12/34/56
EX-3.2
from 10-K 13 pages Amended and Restated By-Laws of Nuvelo, Inc. Adopted December 6, 2007
12/34/56
EX-3.1
from 10-K 16 pages Amended and Restated Certificate of Incorporation of Nuvelo Merger Sub, Inc. Pursuant to Sections 241 and 245 of the General Corporation Law of the State of Delaware
12/34/56